Tumor progression associated with erythropoiesis-stimulating agents.

Abstract

OBJECTIVE To evaluate, characterize, compare, and critique trials reporting increased tumor progression in patients with cancer who are receiving erythropoiesis-stimulating agents (ESAs) that led to Food and Drug Administration (FDA) actions for black box warnings and labeling changes. DATA SOURCES Literature was accessed through MEDLINE (1950-August 2008… (More)
DOI: 10.1345/aph.1L231

Topics

Cite this paper

@article{Newland2008TumorPA, title={Tumor progression associated with erythropoiesis-stimulating agents.}, author={Ashley M Newland and Curtis D Black}, journal={The Annals of pharmacotherapy}, year={2008}, volume={42 12}, pages={1865-70} }